TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2020

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

Jhanelle E Gray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.